SWOG clinical trial number
S0347
A Randomized Study of Weekly Vinorelbine (Navelbine®) Alone or in Combination With Trastuzumab (Herceptin®) (NSC-688097) for Patients With Her-2 Positive Metastatic Breast Cancer Whose Tumors Have Progressed After Taxane + Trastuzumab Combination Therapy – Phase III
0% Accrual
Accrual
0%
Closed
Phase
0% Accrual
Accrual
0%
Research committees
Breast Cancer
Treatment
Trastuzumab
Vinorelbine tartrate
Eligibility Criteria Expand/Collapse
Other Clinical Trials
CTSU-A012301
SWOG Clinical Trial Number
Research Committee(s)
Breast Cancer
Activated
02/05/2025
Open
Phase
S2206
SWOG Clinical Trial Number
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10/30/2023
21% Accrual
Accrual
21%
Open
Phase
S2212
SWOG Clinical Trial Number
Research Committee(s)
Breast Cancer
Activated
07/21/2023
31% Accrual
Accrual
31%
Open
Phase